### Ceftriaxone

**Indication**: Gonococcal infection  
**ICD11 code**: 1B0Z

<table>
<thead>
<tr>
<th><strong>INN</strong></th>
<th>Ceftriaxone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicine type</strong></td>
<td>Chemical agent</td>
</tr>
<tr>
<td><strong>Antibiotic groups</strong></td>
<td>WATCH</td>
</tr>
<tr>
<td><strong>List type</strong></td>
<td>Core</td>
</tr>
<tr>
<td><strong>Additional notes</strong></td>
<td>Do not administer with calcium and avoid in infants with hyperbilirubinaemia.</td>
</tr>
</tbody>
</table>

**Formulations**
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) (EML); 500 mg in vial powder for injection (as sodium salt)

**EML status history**
- First added in 2017 (TRS 1006)
- Changed in 2023 (TRS 1049)

**Sex**: All

**Age**: Adolescents and adults

**Age restriction**: > 41 weeks corrected gestational age

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions

**Wikipedia**: Ceftriaxone

**DrugBank**: Ceftriaxone

---

**Expert Committee recommendation**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.
- replacing the oral liquid formulation of azithromycin (200 mg/5 mL) with powder for oral liquid 200 mg/5 mL on the EML and EMLc.

**EML recommendations: Gonococcal infection**

**First choice**
- ceftriaxone
co-prescribed with azithromycin

**Second choice**
- cefixime
co-prescribed with azithromycin
- spectinomycin
- gentamicin